EVMT Fundamental Analysis - EVOME MEDICAL TECHNOLOGIES I

Fundamental Rating

Overall EVMT gets a fundamental rating of 2 out of 10. We evaluated EVMT against 16 industry peers in the Health Care Equipment & Supplies industry. EVMT has a bad profitability rating. Also its financial health evaluation is rather negative. EVMT does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year EVMT has reported negative net income.

In the past year EVMT had a positive cash flow from operations.

In the past 5 years EVMT always reported negative net income.

EVMT had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

With a decent Return On Assets value of -66.99%, EVMT is doing good in the industry, outperforming 68.75% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-66.99%
ROE	N/A
ROIC	N/A

ROA(3y)-20.97%

ROA(5y)-17.84%

ROE(3y)-154.4%

ROE(5y)-98.04%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 33.80%, EVMT is not doing good in the industry: 62.50% of the companies in the same industry are doing better.

In the last couple of years the Gross Margin of EVMT has declined.

The Profit Margin and Operating Margin are not available for EVMT so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	33.8%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-27.65%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EVMT does not have a ROIC to compare to the WACC, probably because it is not profitable.

EVMT has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, EVMT has more shares outstanding

Compared to 1 year ago, EVMT has a worse debt to assets ratio.

2.2 Solvency

EVMT has an Altman-Z score of -2.59. This is a bad value and indicates that EVMT is not financially healthy and even has some risk of bankruptcy.

EVMT has a better Altman-Z score (-2.59) than 62.50% of its industry peers.

EVMT has a debt to FCF ratio of 3.25. This is a good value and a sign of high solvency as EVMT would need 3.25 years to pay back of all of its debts.

Looking at the Debt to FCF ratio, with a value of 3.25, EVMT belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	3.25
Altman-Z	-2.59

ROIC/WACCN/A

WACC8.49%

2.3 Liquidity

A Current Ratio of 0.51 indicates that EVMT may have some problems paying its short term obligations.

The Current ratio of EVMT (0.51) is worse than 62.50% of its industry peers.

EVMT has a Quick Ratio of 0.51. This is a bad value and indicates that EVMT is not financially healthy enough and could expect problems in meeting its short term obligations.

Looking at the Quick ratio, with a value of 0.24, EVMT is doing worse than 68.75% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	0.51
Quick Ratio	0.24

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 4.50% over the past year.

The Revenue for EVMT has decreased by -39.95% in the past year. This is quite bad

The Revenue has been growing by 73.88% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)4.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-140%

Revenue 1Y (TTM)-39.95%

Revenue growth 3Y438.98%

Revenue growth 5Y73.88%

Sales Q2Q%-49.05%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-400%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-0.65%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

EVMT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVMT. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of EVMT indicates a rather cheap valuation: EVMT is cheaper than 100.00% of the companies listed in the same industry.

		Industry Rank	Sector Rank
P/FCF	0.06
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for EVMT!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EVOME MEDICAL TECHNOLOGIES I

TSX-V:EVMT (5/6/2025, 7:00:00 PM)

0.005

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)05-07 2025-05-07

Earnings (Next)08-11 2025-08-11

Inst Owners9.89%

Inst Owner ChangeN/A

Ins Owners0.19%

Ins Owner ChangeN/A

Market Cap300.85K

Revenue(TTM)48.34M

Net Income(TTM)-23.53M

Analysts80

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.01
P/FCF	0.06
P/OCF	0.06
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.29

EYN/A

EPS(NY)-0.05

Fwd EYN/A

FCF(TTM)0.09

FCFY1784.34%

OCF(TTM)0.09

OCFY1796.34%

SpS0.8

BVpS-0.06

TBVpS-0.19

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-66.99%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	33.8%
FCFM	11.1%

ROA(3y)-20.97%

ROA(5y)-17.84%

ROE(3y)-154.4%

ROE(5y)-98.04%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-27.65%

GM growth 5YN/A

F-Score3

Asset Turnover1.38

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	3.25
Debt/EBITDA	N/A
Cap/Depr	1.09%
Cap/Sales	0.07%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.51
Quick Ratio	0.24
Altman-Z	-2.59

F-Score3

WACC8.49%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)0.22%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)4.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-140%

EPS Next Y-400%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-39.95%

Revenue growth 3Y438.98%

Revenue growth 5Y73.88%

Sales Q2Q%-49.05%

Revenue Next Year-0.65%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y19.82%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year137.83%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y371.62%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y434.86%

OCF growth 3YN/A

OCF growth 5YN/A

EVOME MEDICAL TECHNOLOGIES I / EVMT.CA FAQ

What is the fundamental rating for EVMT stock?

ChartMill assigns a fundamental rating of 2 / 10 to EVMT.CA.

What is the valuation status for EVMT stock?

ChartMill assigns a valuation rating of 2 / 10 to EVOME MEDICAL TECHNOLOGIES I (EVMT.CA). This can be considered as Overvalued.

How profitable is EVOME MEDICAL TECHNOLOGIES I (EVMT.CA) stock?

EVOME MEDICAL TECHNOLOGIES I (EVMT.CA) has a profitability rating of 1 / 10.

What is the expected EPS growth for EVOME MEDICAL TECHNOLOGIES I (EVMT.CA) stock?

The Earnings per Share (EPS) of EVOME MEDICAL TECHNOLOGIES I (EVMT.CA) is expected to decline by -400% in the next year.

EVOME MEDICAL TECHNOLOGIES I (EVMT.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

EVOME MEDICAL TECHNOLOGIES I / EVMT.CA FAQ

What is the fundamental rating for EVMT stock?

What is the valuation status for EVMT stock?

How profitable is EVOME MEDICAL TECHNOLOGIES I (EVMT.CA) stock?

What is the expected EPS growth for EVOME MEDICAL TECHNOLOGIES I (EVMT.CA) stock?